Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MG1-MAGEA3 + Ad-MAGEA3 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Turnstone Biologics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intramuscular, Intratumoral
01
Overview
This is a **combination investigational therapy** consisting of two viral-based immunotherapies (MG1-MAGEA3 and Ad-MAGEA3) and an immune checkpoint inhibitor (pembrolizumab). MG1-MAGEA3 is an oncolytic Maraba virus engineered to express the tumor antigen MAGE-A3, targeting and lysing cancer cells while boosting the immune response[2][4]. Ad-MAGEA3 is a non-replicating adenoviral vaccine expressing MAGE-A3, designed to prime the immune system against this tumor antigen[2][4][7]. Pembrolizumab is a monoclonal antibody targeting PD-1, preventing immune inhibition and promoting T-cell mediated tumor destruction[2][3]. This combination is primarily under investigation for treating advanced solid tumors expressing MAGE-A3 (notably non-small cell lung cancer and metastatic melanoma), especially in patients refractory to standard therapies[1][2][4][5].
- Brand names
- Keytruda
- Other names
- MG1-MAGEA3 plus Ad-MAGEA3 plus pembrolizumabMG-1-MAGEA3 plus Ad-MAGEA3 plus pembrolizumabMG 1-MAGEA3 plus Ad-MAGEA3 plus pembrolizumabOncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)MAGEA3 (Melanoma-associated antigen 3)
Beyond the preview
Go deeper on MG1-MAGEA3 + Ad-MAGEA3 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MG1-MAGEA3 + Ad-MAGEA3 + pembrolizumab.